DEF: Lantern Pharma Seeks Stockholder Approval for Option Repricing

Lantern Pharma Inc. will hold its 2025 Annual Meeting to vote on director elections, a one-time stock option repricing, auditor ratification, and meeting adjournment.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on Friday, September 19, 2025, at 11:00 a.m. Eastern time.
• Stockholders will vote on four key proposals: electing six directors, approving a one-time repricing of certain stock options, ratifying EisnerAmper LLP as the independent registered public accounting firm for fiscal year 2025, and approving an adjournment if necessary.
• The proposed stock option repricing aims to address employee and board member retention by reducing the exercise price of eligible options (those with an exercise price greater than $10.00 per share) to $5.04 per share.
• The repriced options will be subject to an additional 12-month vesting requirement from the Stockholder Approval Date.
• As of July 25, 2025, the company's common stock closing price was $4.24 per share.
• Approximately 25% of the company's total outstanding options, or 314,633 out of 1,235,331, are eligible for this repricing.
• The Board of Directors recommends a 'FOR' vote on all proposals.

Sentiment

Score: 4

Explanation: While the filing outlines standard corporate governance matters and proactive steps like option repricing for retention, the underlying reason for the repricing (significant stock price decline and underwater options) indicates past underperformance. The repricing itself, while necessary for retention, is a consequence of negative market perception and stock value erosion. The expiration of severance rights for two key executives could also be seen as a minor negative.

Positives

• The Board of Directors recommends approval of all proposals, indicating internal alignment and confidence in the proposed actions.
• The stock option repricing is designed to improve employee and board member retention and better align their incentives with investor interests, which could motivate key personnel.
• The repricing strategy is structured to limit accounting expense and further dilution compared to alternative compensation methods like granting new equity awards.
• The company maintains strong corporate governance with a majority of independent directors on its Board and established, active committees (Audit, Compensation, Nominating and Corporate Governance).
• All directors attended at least 75% of Board and Board committee meetings in 2024, demonstrating active oversight.
• The adoption of an Executive Officer Clawback Policy enhances corporate accountability and aligns with recent SEC and Nasdaq regulatory requirements.

Negatives

• The necessity for a stock option repricing stems from a 'significant decline' in the company's stock price over the past four years, which remains at a low level relative to its 2020 and 2021 prices.
• A substantial portion of outstanding stock options are 'underwater,' indicating that previous equity incentives have lost their motivational and retention effect due to poor stock performance.
• The severance and change in control payment provisions for Chief Executive Officer Panna Sharma and Chief Financial Officer David Margrave formally expired on November 15, 2024, potentially reducing their financial security in certain termination scenarios.
• The employment agreement for Chief Scientific Officer Kishor Bhatia was amended to reduce his minimum weekly hours and proportionately adjust his annual base salary to $189,600, effective January 2025.

Risks

• Forward-looking statements in the filing are subject to risks and uncertainties that may cause actual results to differ materially, as detailed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings.
• If stockholders do not approve the stock option repricing, the company risks not being able to retain key service providers due to misaligned and ineffective incentive structures.
• Failure to achieve sufficient votes in favor of Proposals 1, 2, or 3 may necessitate an adjournment of the Annual Meeting to solicit additional proxies, potentially delaying key corporate actions.
• The repricing of stock options may result in certain incentive stock options being converted to nonqualified stock options, which could have different U.S. federal income tax consequences for the optionees.

Future Outlook

The company is evaluating the possibility of further collaborations with Actuate Therapeutics, Inc. after their initial agreement expired. The proposed stock option repricing is intended to better align employee incentives with current company strategy and investor interests, suggesting a focus on future performance and retention of key talent.

Management Comments

• "We urge you to read this information carefully."
• "Whether or not you plan to attend the Annual Meeting in person, and regardless of the number of shares of Lantern that you own, it is important that your shares be represented and voted at the Annual Meeting."
• "Therefore, I urge you to vote your shares of common stock via the Internet or by promptly marking, dating, signing, and returning a proxy card in the envelope provided."
• "On behalf of the Board of Directors of Lantern, we thank you for your participation."
• "The Board has determined that the option Repricing is in the best interest of the Company and its stockholders and recommends a vote For this proposal."
• "Over the past four years, there has been a significant decline in our stock price, which remains at a low level relative to its previous price levels in 2020 and 2021."
• "Although we continue to believe that stock options are a key component of our compensation philosophy, the Eligible Options may be perceived by their holders as having little or no incentive and retention effect due to the extent to which the exercise prices exceed the current stock price."
• "These considerations have led the Board and Compensation Committee to conclude that the Repricing is in the best interests of both the Company and our investors."

Industry Context

Lantern Pharma Inc. operates in the biotechnology sector, specifically focusing on oncology and leveraging AI and genomics for precision therapeutics. The company's collaboration with Actuate Therapeutics, a clinical-stage biopharmaceutical company, aligns with a broader industry trend of strategic partnerships in drug development. The proposed stock option repricing reflects a common challenge faced by biotech companies, particularly those in early stages or experiencing market volatility, where stock price declines can render existing equity incentives ineffective. The company's emphasis on AI and genomics positions it within a rapidly evolving and high-potential area of innovation in drug discovery.

Comparison to Industry Standards

• The stock option repricing, while a common practice for companies with 'underwater' options, is often viewed cautiously by investors due to potential dilution or signaling past underperformance. However, the company's approach of setting the repriced exercise price at 125% of the recent volume-weighted average price and adding a 12-month vesting requirement is a more shareholder-friendly approach compared to a direct repricing to the current market price or a value-for-value exchange that might offer fewer new awards.
• The company's board composition, with five out of six independent directors, meets or exceeds typical Nasdaq listing standards for independence, demonstrating strong corporate governance practices.
• The engagement of an independent compensation consultant (Anderson Pay Advisors) by the Compensation Committee is a standard best practice for public companies to ensure executive compensation is competitive and aligned with performance.
• The adoption of a clawback policy is a direct response to recent SEC and Nasdaq mandates, bringing the company into compliance with current industry governance standards and enhancing accountability.

Management Changes

Corporate Governance

Related Party Transactions

• On November 21, 2023, the company purchased 145,348 shares of its common stock from Bios Fund I QP, LP and Bios Fund I, LP (Bios Entities) at a purchase price of $3.44 per share, for a total of $499,997.12. The Bios Entities collectively beneficially own approximately 9.98% of the company's outstanding common stock.
• The company had a Collaboration Agreement with Actuate Therapeutics, Inc. (which expired on March 31, 2024), from which it received 25,000 restricted shares of Actuate stock (now 13,889 shares after Actuate's IPO and reverse stock split). Certain Bios Equity Entities hold substantial beneficial ownership interests in both Lantern Pharma and Actuate, and Leslie W. Kreis, Jr., a former Lantern director, is a director of Actuate.

Stakeholder Impact

• Shareholders will directly participate in key corporate decisions by voting on director elections, the stock option repricing, and auditor ratification. The repricing aims to re-align management incentives, which could benefit long-term shareholder value if successful, but also reflects past stock price underperformance.
• Employees and Board members are directly impacted by the proposed stock option repricing, which seeks to restore the incentive value of their equity awards and improve retention. The additional 12-month vesting requirement ties their incentives to continued service.
• The company's independent registered public accounting firm, EisnerAmper LLP, will continue its role, ensuring financial oversight and compliance.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on September 19, 2025, to vote on the proposed agenda items.
• Mailing of the Annual Report, Notice of Meeting, Proxy Statement, and Proxy Card to stockholders on or about August 11, 2025.
• If approved by stockholders, eligible options will be repriced to $5.04 per share, subject to an additional 12-month vesting period.
• The company will continue to evaluate the possibility of further collaborations with Actuate Therapeutics, Inc.

Key Dates

Recommendation

The filing primarily concerns routine corporate governance matters and a stock option repricing. While the repricing is a necessary step to re-incentivize management given the significant decline in stock price, it also highlights past underperformance. The company's focus on AI and genomics in oncology is promising, but this filing does not provide new operational or financial results to warrant a 'buy' or 'sell' recommendation. The repricing aims to stabilize and retain key talent, which is a positive for long-term stability, but the underlying stock performance issues suggest a 'hold' until more substantive operational or financial improvements are demonstrated.

Keywords

Lantern Pharma, Proxy Statement, SEC filing, Stock Options, Option Repricing, Corporate Governance, Annual Meeting, Executive Compensation, Biotechnology, Oncology, AI in Pharma, Precision Therapeutics